» Articles » PMID: 35299958

Peptide Model of the Mutant Proinsulin Syndrome. II. Nascent Structure and Biological Implications

Overview
Specialty Endocrinology
Date 2022 Mar 18
PMID 35299958
Authors
Affiliations
Soon will be listed here.
Abstract

Toxic misfolding of proinsulin variants in β-cells defines a monogenic diabetes syndrome, designated (MIDY). In our first study (previous article in this issue), we described a one-disulfide peptide model of a proinsulin folding intermediate and its use to study such variants. The mutations (Leu→Pro, Leu→Pro, and Phe→Ser) probe residues conserved among vertebrate insulins. In this companion study, we describe H and H-C NMR studies of the peptides; key NMR resonance assignments were verified by synthetic C-labeling. Parent spectra retain nativelike features in the neighborhood of the single disulfide bridge (cystine B19-A20), including secondary NMR chemical shifts and nonlocal nuclear Overhauser effects. This partial fold engages wild-type side chains Leu, Leu and Phe at the nexus of nativelike α-helices α and α (as defined in native proinsulin) and flanking β-strand (residues B24-B26). The variant peptides exhibit successive structural perturbations in order: parent (most organized) > Ser >> Pro > Pro (least organized). The same order pertains to (a) overall α-helix content as probed by circular dichroism, (b) synthetic yields of corresponding three-disulfide insulin analogs, and (c) ER stress induced in cell culture by corresponding mutant proinsulins. These findings suggest that this and related peptide models will provide a general platform for classification of MIDY mutations based on molecular mechanisms by which nascent disulfide pairing is impaired. We propose that the syndrome's variable phenotypic spectrum-onsets ranging from the neonatal period to later in childhood or adolescence-reflects structural features of respective folding intermediates.

Citing Articles

Synthetic studies of the mutant proinsulin syndrome demonstrate correlation between folding efficiency and age of diabetes onset.

Dhayalan B, Chen Y, Ni C, Weiss M Int J Pept Res Ther. 2025; 31(1).

PMID: 39866851 PMC: 11759498. DOI: 10.1007/s10989-024-10665-z.


Peptide Model of the Mutant Proinsulin Syndrome. I. Design and Clinical Correlation.

Dhayalan B, Glidden M, Zaykov A, Chen Y, Yang Y, Phillips N Front Endocrinol (Lausanne). 2022; 13:821069.

PMID: 35299972 PMC: 8922534. DOI: 10.3389/fendo.2022.821069.

References
1.
Kaarsholm N, Norris K, Jorgensen R, Mikkelsen J, Ludvigsen S, Olsen O . Engineering stability of the insulin monomer fold with application to structure-activity relationships. Biochemistry. 1993; 32(40):10773-8. DOI: 10.1021/bi00091a031. View

2.
Nilges M, Clore G, Gronenborn A . Determination of three-dimensional structures of proteins from interproton distance data by hybrid distance geometry-dynamical simulated annealing calculations. FEBS Lett. 1988; 229(2):317-24. DOI: 10.1016/0014-5793(88)81148-7. View

3.
Markussen J . Comparative reduction/oxidation studies with single chain des-(B30) insulin and porcine proinsulin. Int J Pept Protein Res. 1985; 25(4):431-4. DOI: 10.1111/j.1399-3011.1985.tb02197.x. View

4.
Shen Y, Delaglio F, Cornilescu G, Bax A . TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts. J Biomol NMR. 2009; 44(4):213-23. PMC: 2726990. DOI: 10.1007/s10858-009-9333-z. View

5.
Schwarzinger S, Kroon G, Foss T, Wright P, Dyson H . Random coil chemical shifts in acidic 8 M urea: implementation of random coil shift data in NMRView. J Biomol NMR. 2000; 18(1):43-8. DOI: 10.1023/a:1008386816521. View